**SIGMA²: A system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes**

Raj Chari* 1, Bradley P Coe 1, Craig Wedseltoft 1, Marie Benetti 1, Ian M Wilson 1, Emily A Vucic 1, Calum MacAulay 2, Raymond T Ng 3 and Wan L Lam 1

**Address:** 1 Department of Cancer Genetics and Developmental Biology, BC Cancer Agency Research Centre, Vancouver, BC, Canada, 2 Department of Cancer Imaging, BC Cancer Agency Research Centre, Vancouver, BC, Canada and 3 Department of Computer Science, University of British Columbia, Vancouver, BC, Canada

Email: Raj Chari* - rchari@bccrc.ca; Bradley P Coe - bcoe@bccrc.ca; Craig Wedseltoft - craigtw@interchange.ubc.ca; Marie Benetti - mebenetti@shaw.ca; Ian M Wilson - iwilson@bccrc.ca; Emily A Vucic - evucic@bccrc.ca; Calum MacAulay - cmacaula@bccrc.ca; Raymond T Ng - mg.cs.ubc.ca; Wan L Lam - wanlam@bccrc.ca

* Corresponding author

**Abstract**

**Background:** High throughput microarray technologies have afforded the investigation of genomes, epigenomes, and transcriptomes at unprecedented resolution. However, software packages to handle, analyze, and visualize data from these multiple ‘omics disciplines have not been adequately developed.

**Results:** Here, we present SIGMA², a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes. Multi-dimensional datasets can be simultaneously visualized and analyzed with respect to each dimension, allowing combinatorial integration of the different assays belonging to the different ‘omics.

**Conclusion:** The identification of genes altered at multiple levels such as copy number, loss of heterozygosity (LOH), DNA methylation and the detection of consequential changes in gene expression can be concertedly performed, establishing SIGMA² as a novel tool to facilitate the high throughput systems biology analysis of cancer.

**Background**

Multiple mechanisms of gene disruption have been shown to be important in the development of cancer. Genetic alterations (mutations, changes in gene dosage, allele imbalance) and epigenetic alterations (changes in DNA methylation and histone modification states) are responsible for changing the expression of genes. High throughput approaches have afforded the ability to interrogate the genomic, epigenomic and gene expression (transcriptomic) profiles at unprecedented resolution [1-6]. However, a gene can be disrupted by one or by a combination of mechanisms, therefore, investigation in a single ‘omics dimension (genomics, epigenomics, or transcriptomics) alone cannot detect all disrupted genes in a given tumor. Moreover, individual tumors may have different patterns of gene disruption, by different mechanisms for a given gene while achieving the same net effect on phenotype. Hence, a multi-dimensional approach is...
required to identify the causal events at the DNA level and understand their downstream consequences.

The current state of software for global profile comparison typically focuses on analyzing and displaying data from a single dimension, for example CGH Fusion (infoQuant Ltd, London, UK) for DNA copy number profile analysis and GeneSpring (Agilent Technologies, Santa Clara, CA, USA) for gene expression profile analysis. Software for integrative analysis have been restricted to working with datasets derived from limited combination of technology platforms (Table 1) [7-10]. Though different software can analyze data generated from different platforms, the ability to perform meta-analysis using data from multiple microarray platforms is limited to a small number of software packages. Consequently, integrative analysis of cancer genomes typically involves no more than two types of data, most commonly the integration of gene dosage and gene expression data [11-16] and recently expanded to integrating allelic information [17]. Software to perform multi-dimensional analysis are therefore greatly in demand.

Here, we present SIGMA2, a novel software package which allows users to integrate data from the various 'omics disciplines such as genomics, epigenomics and transcriptomics. Multi-dimensional datasets can be simultaneously compared, analyzed and visualized with respect to individual dimensions, allowing combinatorial integration of the different assays belonging to the different 'omics. The identification of genes altered at multiple levels such as copy number, LOH, DNA methylation and the detection of consequential changes in gene expression can be concordantly performed, establishing SIGMA2 as a tool to facilitate the high throughput systems biology analysis of cancer. SIGMA2 is freely available for academic and research use from our website, http://www.flintbox.com/technology.asp?Page=3716.

Implementation
SIGMA2 is implemented in Java, and requires version 1.6+ of the runtime compiler. In addition, the statistical package R and database application MySQL are also required. The java interface communicates with MySQL using a JDBC connector and with R using the JRI package by JGR (Figure 1). MySQL is used for data storage and querying while R is used for the segmentation and statistical analysis. All genomic coordinate information was obtained from University of California Santa Cruz (UCSC) genome databases [18].

Results and discussion
Look and feel of SIGMA2
The novel multi-dimensional 'omics data analysis software SIGMA2 is built on the framework of a facile visualization tool called SIGMA, which can display alignment of genomic data from a built-in static database [7]. The arsenal of functionalities introduced in SIGMA2 is shown in Table 1.

Description of application scope and functionality
SIGMA2 is built to handle a variety of analysis techniques typically used in the high-throughput study of cancer, allowing the combinatorial integration of multiple 'omics disciplines. The hierarchy, which underlies the program, groups data into genome, epigenome, and transcriptome is shown in Figure 2A and the overall functionality map is given in Figure 2B and listed in Table 2. With each 'omics disciplines.
dimension, data sets may be imported representing any of the major types of biological measurements being assayed, for example, (i) examining both DNA copy number and LOH assays within the genomic bundle, (ii) examining both DNA methylation and histone modification status within the epigenomics bundle, and (iii) examining both gene expression profiles and microRNAs expression assays within the transcriptomic bundle. Each assay may branch into data sources from a multitude of technology platforms.

**Approach to integration between array platforms and assays**

SIGMA\(^2\) treats all data in the context of genome position based on the relevant human genome build using the UCSC genome assemblies. An interval-based approach is used to sample across different array platforms and assays and data from each interval are merged together. Briefly, this is done by querying data at fixed genomic intervals for each platform and subsequently taking an average of the measurements within each interval. The algorithm is listed in Figure 3.

**Format requirements of input data**

Standard tab-delimited text files are used for the input of data for all of the assay types. For genomic data, specifically array CGH, normalization is recommended using external algorithms such as *CGH-Norm* and MANOR [19,20]. Segmentation analysis can be performed within SIGMA\(^2\), but results from external analysis can be imported and used in the consensus calling feature. The algorithms which can be called within SIGMA\(^2\) currently include *DNACopy* and *GLAD* [21,22]. Multiple sample batch importing is available to facilitate efficient loading of datasets. To utilize this, the user must create an information file which describes each sample in the dataset. Formatting requirements of the information file are specified in the manual. Alternatively, for Affymetrix SNP array analysis, data should also be pre-processed and normalized using the appropriate software, such as *CNAG* before importing into SIGMA\(^2\) [23]. Genotyping calls should be made prior to importing, using the "AA", "AB" and "BB" convention. If the genotype call does not exist, "NC" must be specified. For epigenomic data, data from affinity based-approaches (MeDIP [6] and ChIP [24]) should contain a value representing the level of enrichment and the genomic coordinates for each spot. Similarly, for bisulphite-based approaches [25], a percent of converted CpGs should be provided along with the genomic coordinates for each spot. Finally, for transcriptome data, gene expression data from Affymetrix experiments can be directly imported and processed as CEL files and are normalized using the MAS 5.0 algorithm implemented in the "affy" package of R. For any assay type, custom data can be imported whereby the user provides a map of the platform based on the given genome build, and the unique identifier for the map must be used for the data generated from those experiments.
(A) Data hierarchy describing the relationship between platforms, assays and 'omics disciplines. (B) Functionality map of SIGMA². List of the various functions and the output from that function that can be performed given the number of samples or sample groups and dimensions. Multiple sample analysis (single group and two group) are microarray platform independent. Functions listed in boxes are in addition to those listed in the box preceding the arrows.
Table 2: Summary of Input, analysis, output for each dimension

| ’Omics classification | Assay(s) measured | Input | Functionality*** | Output |
|-----------------------|-------------------|-------|------------------|--------|
| Genomics              | Copy number       | Array CGH | Segmentation | Regions of gain and loss |
|                       |                   |        | Direct thresholding | Gene lists for further analysis |
|                       |                   |        | Moving average-based thresholding | High-resolution karyogram images |
| Genomics              | LOH               | SNPs*  | LOH based on consecutive altered markers | Regions of LOH |
| Genomics              | LOH               | Microsatellite markers | Same as above | Same as above |
| Genomics              | Copy number, LOH  |        | Identify regions of uniparental disomy (UPD); LOH with no copy number change | Regions of enrichment and lack of methylation |
| Genomics              |                   |        | Gene lists for further analysis | Gene lists for further analysis |
| Epigenomics           | DNA methylation   | MeDIP + array CGH | Direct thresholding | Regions of enrichment and lack of methylation |
| Epigenomics           | DNA methylation   | Bilsulphite-based | Moving average-based thresholding | Gene lists for further analysis |
| Epigenomics           | Histone modification states | ChIP-on-chip | Z-transformation of moving average | Gene lists for further analysis |
| Epigenomics           | DNA methylation, Histone modification states | | Regions of mutually exclusive change between chromatin state and DNA methylation |
| Transcriptomics       | Gene expression** | Microarrays | Heatmap visualization, clustering | Expression of genes of interested based on DNA analysis |
| Transcriptomics       | Gene expression** | SAGE | Heatmap visualization, clustering | Expression of genes of interested based on DNA analysis |
| Genomics, Transcriptomics | Copy number, Gene expression | | Statistical comparison of expression in regions of copy number difference (two group analysis) | Genes whose expression is strongly regulated by copy number |
| Genomics, Epigenomics | Copy number, DNA methylation | | Identify regions of concerted change in both copy number and methylation ("two-hit") | p-values for associations |
| Genomics, Epigenomics | LOH, DNA methylation | | Identify allele-specific methylation events | p-values for group comparison |
| Genomics, Epigenomics | Copy number, LOH, DNA methylation, Histone modification Gene Expression | | Identify co-ordinate genetic, epigenetic and gene expression changes | Genes altered at multiple levels |

* Affymetrix and Illumina data must be pre-processed prior to import; ** functionality invoked in the context of genetic and epigenetic data analyses; *** aligned to genome features (Database of genomic variants, CpG Islands, microRNAs etc.)

Description of user interface

The main user interface in SIGMA2 utilizes a tabbed window-pane which allows the user to open multiple visualizations simultaneously (Figure 4). The left part of the window manages the analyses and projects which belong to the current user and button shortcuts for the main func-
tionality are spread along the top of the window. Using an example of an array CGH profile from the Agilent 244K platform, we demonstrate the step-wise interrogation of a region of interest [26]. Briefly, using the highlighting tool-bar button, the user can select a region of interest and subsequently, by clicking the right mouse button, the user can search for annotated genes within the specified genomic coordinates.

Analysis of data from a single assay type
The first, and most basic, level of analysis is from a single assay type. For array CGH, multiple options for segmentation algorithms are available within the program and results from externally run segmentation can be imported as well. However, each segmentation algorithm has its advantages and disadvantages depending on the type of data used and the quality of data at hand. A unique feature of SIGMA is the ability to take a consensus of multiple algorithms using "And" or "Or" logic between algorithms. Moreover, a level of consensus can be specified (Figure 5A). For example, if an experiment is analyzed using five approaches, the user can select areas of gain and loss which were detected by one algorithm, at least three algorithms, all five algorithms, etc. For LOH, basic analysis using the number of consecutive markers that exhibit LOH is used to determine its status. Affinity-based approaches for DNA methylation and histone modification states or bead-based percentage of CpG island methylation is analyzed by either direct thresholding or z-transform thresholding. For any of the different assay types, when examining across a number of samples, a frequency of alteration can be calculated and plotted.

For data from different array platforms, but assaying the same biological measurement, the algorithm for integration is used to derive common data. This feature is most applicable to DNA copy number data due to the number of array CGH platforms. This allows for better utilization of publicly available data and thus, increasing sample size for statistical analysis. Similar to the multiple sample analysis of data on the sample platform, a frequency of altered states can be generated and plotted. Figure 5A shows the concerted analysis of a sample profiled on the Affymetrix 500K SNP array, Agilent 244K CGH array and the whole genome tiling path BAC array (Figure 5B).

Analysis of data from multiple assays in a given 'omics dimension
Within a given 'omics dimension, multiple assay types can be analyzed in combination. For example, it is useful to investigate copy number and LOH and the interplay between DNA methylation and different states of histone modification. Typically, in regions of copy number loss, LOH is also observed. However, LOH can also occur in

```
numSamples <- number of samples
for chr <- 1: 24
  k <- 10000
  chrEnd <- length of chromosome
  intervals <- chrEnd % k
  data <- array[intervals, numSamples]
  currentInterval <- 0
  for pos<0, pos< chrEnd, pos+=k
    for sampleNum <- 1:numSamples
      data[currentInterval,sampleNum] <- data from sample for interval pos and pos+k*
    end
  currentInterval <- currentInterval + 1
end

*if multiple data points exist in the interval, an average is used. If no data exists, blank is returned. If it is array CGH data that is segmented, data is assumed to exist for any genomic position.

Figure 3
Algorithm for integrating between different array platforms. Data for every platform is matched to genomic position. Subsequently, an interval-based approach is used to systematically query data for each interval. In this figure, the interval, k, is 10 kb in size. By converting everything to genomic position, samples sets of the same disease type but on different array platforms can be aggregated affording the user with additional statistical power.
```
regions which are copy number neutral, indicating a change in allelic status which is not interpretable by one dimension alone. Here, we show a sample for which copy number and LOH information exists, a region of copy number loss associated with LOH (Figure 6). In terms of epigenetics, DNA methylation and states of histone methylation and acetylation have been known to be biologically relevant. With high throughput technologies available to assay these dimensions, this type of analysis will become more prevalent.

**Combinatorial analysis of multiple 'omics dimensions – gene dosage and gene expression**

The most common analysis of multiple 'omics dimensions is the influence of the genome on the transcriptome. A number of software packages have started to incorporate approaches to examining gene dosage and gene expression [8,9,27]. In SIGMA², there are multiple functionalities which allow the user to link DNA copy number to gene expression. For a single group of samples, with matching DNA copy number and gene expression pro-
files, the user can determine associations through two main options: a) using a correlation-based approach, correlating the log ratios with the normalized gene expression intensities and b) using a statistical-based approach comparing the expression in samples with copy number changes against those without copy number change utilizing the Mann Whitney U test, analogous to approaches taken in previous studies [27]. Spearman, Kendall or Pearson correlation coefficients can be calculated for option a). Similarly, this functionality is also available for correlating epigenetic profiles and gene expression.

In addition to single group analysis, two-dimensional genome/transcriptome analysis can be applied to two-group comparison analysis. For example, if patterns of copy number alterations are compared between two groups and a particular region is more frequently gained in one group than another, the expression data can subsequently compared between the groups of sample to determine if there is an association between gene dosage and gene expression. That is, we would expect the group with more frequent copy number gain to have higher expression than the other group. Notably, this functionality does not require both copy number and expression data to exist for the same sample, but allows the user to select an independent dataset for expression data comparisons (Figure 7).

**Group comparison analysis – single ‘omics dimension**

Finally, for two groups of samples, the user can compare the distribution of changes between two groups to determine if the patterns are statistically different using a Fisher’s Exact test. For DNA copy number, it is the distribution of gain and losses; for DNA methylation or histone modification states, the proportion of samples that meet the threshold of enrichment for each group (low or high); and for LOH, proportion of samples with LOH for a region for each group.

**Group comparison analysis – integrating multiple ‘omics dimensions**

This type of analysis can be performed with a single sample or multiple samples, thus allowing combinatorial (“and”) analysis for large datasets. In addition, the user can also identify “or” events, where a change in any of the dimensions can be flagged. This is more important in
multi-sample datasets as one dimension may not capture complex alterations of a particular region.

**Multi-dimensional analysis of a breast cancer genome**
Using the breast cancer cell line HCC2218, we show the integration of genomic, epigenomic, and transcriptomic data. Interestingly, when we examine the ERBB2 gene on chromosome 17, we show concurrent amplification, LOH, loss of methylation and drastic increase in gene expression (Figure 8). ERBB2 has shown to be an important gene in breast cancer development and therapeutic intervention. This demonstrates the value in integrating multiple dimensions to understand complex alteration patterns in disease samples where multiple causes can lead to a single effect.

**Exporting data and results**
High resolution images can be exported for all types of visualizations in SIGMA2. Histogram plots of gene expression, heatmaps with clustering of gene expression, karyogram plots and frequency histogram plots are the main types of visualization available. Frequency histogram data which is used to generate the plots can also be exported. Integrated plots with data plotted serially or overlaid are also available for analysis involving multiple genomic and epigenomic dimensions. Genes which are obtained
from the conjunctive (And) and disjunctive (Or) multi-dimensional analysis can be exported with their status. Results of statistical analysis such as Fisher’s exact comparisons and U-test comparisons of gene expression can be exported against annotate gene lists based on user-specified human genome builds. Currently, April 2003 (hg15), May 2004 (hg17) and March 2006 (hg18) are the available genome builds [18]. As new builds are released, sup-

Figure 7
A two-group two dimensional comparison of 37 NSCLC and 16 SCLC cancer cell lines. First, segmentation analysis is performed to delineate gains and losses in each sample. Next, a statistical comparison of the distribution of gains and losses between the two groups is done using the Fisher’s exact test. (A) Using the interactive search, one of the regions of difference identified is on chromosome 7, with a NSCLC and SCLC sample aligned next to each other. The NSCLC has a clear segmental gain of that region, with the SCLC not having the gain. The right-most graph is a frequency plot summary of two sample sets (NSCLC and SCLC). NSCLC is color-coded in red while SCLC in green, and the overlap appears in yellow. The frequency of chromosome arm 7p gain is higher in the red group. (B) A heatmap is shown representing 15 NSCLC and 15 SCLC gene expression profiles, of the specific genes in the region highlighted in yellow. (C) When examining gene expression data of EGFR specifically, a gene in this region, we can see that the expression is drastically higher in NSCLC vs. SCLC, as predicted by the higher frequency of gain in NSCLC vs. SCLC of that region. Gene expression data are represented as log2 of the normalized intensities.

Figure 8
Multi-dimensional perspective of chromosome 17 of the HCC2218 breast cancer cell line. Copy number, LOH, and DNA methylation, and profiling identifies an amplification of ERBB2 coinciding with allelic imbalance and loss of methylation. When examining the gene expression, the expression of HCC2218 is significantly higher than a panel of normal luminal and myoepithelial cell lines [29].
port for those builds will be available. Finally, data from multi-platform integration can be exported based on based pair position for additional external analysis if necessary.

**Conclusion**

With the increase in high-throughput data covering multiple dimensions of the genome, epigenome and transcriptome, the approaches and tools to analyze this data must advance accordingly to handle, analyze and interpret this data in an integrated manner. SIGMA² meets these requirements and provides the framework for the incorporation of data from future approaches and technologies. Specifically, with the movement from array to sequence-based technologies, the ability to assimilate sequence data with the various omics data sets will become a future requirement of software packages.

**Availability and requirements**

Project name: SIGMA²

Operating system(s): Java SE V.1.6+, R Project V.2.5+, Windows XP or Vista

License: Free for academic and research use; commercial users please contact

**Authors’ contributions**

RC designed and developed the software and wrote the manuscript. BPC contributed to the design and development of the software. CW and MB contributed significantly to software development. IMW and EAV contributed to beta testing and ideas for refinement of software. CM and RTN contributed concepts for implementation of data integration and statistical analyses. WLL is the principle investigator of this study. All authors contributed to the critical reading and editing of the manuscript.

**Acknowledgements**

We thank William W. Lockwood and Timon P.H. Buys for useful discussion and critical reading of manuscript, Ashleen Shadeo for providing data for breast cancer samples, and Anna Chu, Byron Cline, Devon Macey, Andrew Thomson, Lan Wei, Reginald Sacdalan, Tiffany Chao, and Laura Aslan for help with software development. This work was supported by funds from Canadian Institutes for Health Research (CIHR), NIH (NIDCR) R01 DE15965, and Genome Canada/British Columbia. RC and IMW were supported by scholarships from CIHR and the Michael Smith Foundation for Health Research.

**References**

1. Garnis C, Buys TP, Lam WL: Genetic alteration and gene expression modulation during cancer progression. Mol Cancer 2004, 3:9.

2. Ishkhanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coo BP, Snijders A, Albertson DG, Pinkel D, Marra MA, et al.: A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004, 36(3):299-303.

3. Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiak E, Figueroa ME, Glass JL, Chen Q, Montagna C, et al.: Comparative isochizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006, 16(8):1046-1055.

4. Lockwood WW, Chari R, Chi B, Lam WL: Recent advances in array comparative genomic hybridization technologies and their applications in human genetics. Eur J Hum Genet 2006, 14(2):139-148.

5. Rauch T, Li H, Wu X, Pfeifer GP: MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006, 66(16):7939-7947.

6. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37(8):853-862.

7. Gerlinger M, Deininger M, Khochbin D, Davies JJ, MacAulay C, Lam WL: SIGMA: a system for integrated genomic microarray analysis of cancer genomes. BMC Genomics 2006, 7:324.

8. Conde L, Montaner D, Burguet-Castell J, Tarraga J, Medina I, Al-Shahrour F, Dopazo J: ISACGH: a web-based environment which includes functional profiling. Nucleic Acids Res 2007; W81-85.

9. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, et al.: VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006, 22(17):2066-2073.

10. Chi B, deLeeuw RJ, Coo BP, Ng RT, MacAulay C, Lam WL: MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 2008, 9:243.

11. Carrasquillo DM, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatri D, Protopopova M, et al.: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9(4):318-325.
22. Venkatraman ES, Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23(6):657-663.

23. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, et al.: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005, 65(14):6071-6079.

24. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M: Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. Embo J 2003, 22(23):6335-6345.

25. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, et al.: High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006, 16(3):383-393.

26. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL: Resolving the resolution of array CGH. Genomics 2007, 89(5):647-653.

27. van Wieringen WN, Belien JA, Vosse SJ, Achame EM, Ylstra B: ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data. Bioinformatics 2006, 22(15):1919-1920.

28. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, et al.: An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004, 64(9):3060-3071.

29. Grigoriadis A, Mackay A, Reis-Filho JS, Szeel D, Iseli C, Stevenson BJ, Jongeneel CV, Valgeirsson H, Fenwick K, Irvani M, et al.: Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006, 8(5):R56.